EP Patent

EP4324475A1 — Compositions of glp-1 peptides and preparation thereof

Assigned to Novo Nordisk AS · Expires 2024-02-21 · 2y expired

What this patent protects

The invention relates to pharmaceutical compositions comprising a first type of granules and a second type of granules, wherein said first type of granules comprises a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid, and wherein said second type of granules comprises a GLP-1 p…

USPTO Abstract

The invention relates to pharmaceutical compositions comprising a first type of granules and a second type of granules, wherein said first type of granules comprises a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid, and wherein said second type of granules comprises a GLP-1 peptide, as well as the intermediate granules, processes for the preparation of the granules and compositions, and use thereof in medicine.

Drugs covered by this patent

Patent Metadata

Patent number
EP4324475A1
Jurisdiction
EP
Classification
—
Expires
2024-02-21
Drug substance claim
No
Drug product claim
No
Assignee
Novo Nordisk AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.